Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-26. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
The ionization efficiency of DESI is complex and depends on several parameters such as, surface effects, electrospray parameters, chemical parameters and geometric parameters. Surface effects include chemical composition, temperature and electric potential applied. Electrospray parameters include electrospray voltage, gas and liquid flow rates. Chemical parameters refers to the sprayed solvent composition, e.g. addition of NaCl. Geometric parameters are α, β, d1 and d2 (see figure on the right). Furthermore, α and d1 affect the ionization efficiency, while β and d2 affect the collection efficiency. Results of a test performed on a variety of molecules to determine optimal α and d1 values show that there are two sets of molecules: high molecular weight (proteins, peptides, oligosaccharide etc.) and low molecular weight (diazo dye, stereoids, caffeine, nitroaromatics etc.). The optimal conditions for the high molecular weight group are high incident angles (70–90°) and short d1 distances (1–3 mm). The optimal conditions for the low molecular weight group are the opposite, low incident angles (35–50°) and long d1 distances (7–10 mm). These test results indicate that each group of molecules has a different ionization mechanism; described in detail in the Principle of operation section. The sprayer tip and the surface holder are both attached to a 3D moving stage which allow to select specific values for the four geometric parameters: α, β, d1 and d2.
Pempel (1966), professor of political science and former director of the Institute of Asian Studies at the University of California, Berkeley Roger Sanjek (1966), professor of anthropology at Queens College, City University of New York David Weissbrodt (1966), legal scholar at the University of Minnesota Law School known for drafting the Minnesota Protocol Jay Winter (1966), World War I specialist at Yale University Paul Gewirtz (1967), constitutional law scholar Karl Klare (1967), critical legal studies theorist Norman Friedman (1967), author and naval analyst Mott T. Greene (1967), historian of science, professor at University of Puget Sound Reza Sheikholeslami (1967), Soudavar Professor of Persian Studies at Wadham College, Oxford Jeremy Siegel (1967), professor of the Wharton School of the University of Pennsylvania Terrell Carver (1968), political theorist; professor at the University of Bristol Samuel R. Gross (1968), professor at the University of Michigan Law School; editor of the National Registry of Exonerations project Charles Lindholm (1968), University Professor of Anthropology at Boston University Alfred W. McCoy (1968), historian of Southeast Asia; professor at the University of Wisconsin–Madison Lawrence Susskind (1968), urban planner and mediator; professor at the Massachusetts Institute of Technology Jerry Avorn (1969), professor at the Harvard Medical School William Boone Bonvillian (1969), scholar of innovation technology policy, former director of MIT's Washington, D.C.
==== Secret genetic research ==== Controversy has also erupted in some countries over collection and storage of blood or DNA samples by government agencies during the routine newborn blood screen. In the United States, it was revealed that Texas had collected and stored blood and DNA samples on millions of newborns without the parents' knowledge or consent. These samples were then used by the state for genetic experiments and to set up a database to catalog all of the samples/newborns. As of December 2009, samples obtained without parents' consent between 2002 and 2009 were slated to be destroyed following the settlement of "a lawsuit filed by parents against the Texas Department of Health Services and Texas A&M; for secretly storing and doing research on newborn blood samples." A similar legal case was filed against the State of Minnesota. Over 1 million newborn bloodspot samples were destroyed in 2011 "when the state's Supreme Court found that storage and use of blood spots beyond newborn screening panels was in violation of the state's genetic privacy laws.". Nearly US$1 million was required to be paid by the state for the attorney's fees of the 21 families who advanced the lawsuit.
Gavi's main objective is vaccination programs. Gavi has been the main funder of vaccination in low and middle income countries. In 2012, the first Médecins Sans Frontières (MSF) "The right shot" report criticized Gavi for focusing on funding expensive new vaccines and neglecting to give children low-cost older ones. "Twenty percent of the world's children aren't even getting the basic vaccines", MSF's vaccine policy adviser said. MSF criticized the Global Vaccine Action Plan (GVAP), a WHO global collaboration of which Gavi is listed as a leader, as flawed for failing to help those 20%, which is some 19 million infants.
Sources: en.wikipedia.org
The White Liberation Movement (Afrikaans: Blanke Bevrydingsbeweging, abbreviated BBB) was a South African neo-Nazi organisation which became infamous after being banned under the Apartheid regime, the first right-wing organisation to be banned as such. It regarded itself as the most far-right organisation in South Africa.
restriction site Also restriction recognition site. A short, specific sequence of nucleotides (typically 4 to 8 bases in length) that is reliably recognized by a particular restriction enzyme. Because restriction enzymes usually bind as homodimers, restriction sites are generally palindromic sequences spanning both strands of a double-stranded DNA molecule. Restriction endonucleases cleave the phosphate backbone between two nucleotides within the recognized sequence itself, while other types of restriction enzymes make their cuts at one end of the sequence or at a nearby sequence.
The structure of an ideal (infinitely long) single-walled carbon nanotube is that of a regular hexagonal lattice drawn on an infinite cylindrical surface, whose vertices are the positions of the carbon atoms. Since the length of the carbon-carbon bonds is fairly fixed, there are constraints on the diameter of the cylinder and the arrangement of the atoms on it. In the study of nanotubes, one defines a zigzag path on a graphene-like lattice as a path that turns 60 degrees, alternating left and right, after stepping through each bond. It is also conventional to define an armchair path as one that makes two left turns of 60 degrees followed by two right turns every four steps. On some carbon nanotubes, there is a closed zigzag path that goes around the tube. One says that the tube is of the zigzag type or configuration, or simply is a zigzag nanotube. If the tube is instead encircled by a closed armchair path, it is said to be of the armchair type, or an armchair nanotube. An infinite nanotube that is of one type consists entirely of closed paths of that type, connected to each other. The zigzag and armchair configurations are not the only structures that a single-walled nanotube can have. To describe the structure of a general infinitely long tube, one should imagine it being sliced open by a cut parallel to its axis, that goes through some atom A, and then unrolled flat on the plane, so that its atoms and bonds coincide with those of an imaginary graphene sheet—more precisely, with an infinitely long strip of that sheet.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.